24 May 2013
Keywords: complegen, berlex, sign, discovery, deal, genetics, based
Article | 14 April 2003
CompleGen, a genetics based drug discovery company, and BerlexBiosciences, a US affiliate of Germany's Schering AG, have entered into
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 April 2003
23 May 2013
© 2013 thepharmaletter.com